Enanta Pharmaceuticals announces data from Phase 2b study related to ABT-450

theflyonthewall.com

Enanta Pharmaceuticals announced that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

Rates

View Comments